Hillstream BioPharma, Inc. (HILS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.1000 |
| Open | 1.1772 |
| Bid | 1.2600 x 1100 |
| Ask | 1.2700 x 1100 |
| Day's Range | 1.1300 - 1.6799 |
| 52 Week Range | 0.6500 - 4.2400 |
| Volume | |
| Avg. Volume | 1,329,727 |
| Market Cap | 14.412M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3910 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for HILS
Related Research
- Hillstream BioPharma, Inc.Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.RatingFair ValueEconomic Moat8 days agoArgus Research
- GlobeNewswire
Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13
BRIDGEWATER, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will attend the 12th Annual World Orphan Drug Congress USA 2022, being held at the Hynes Convention Center in Boston, on July 11-13, 2022. Mr. Randy Milby, Founder a
- Simply Wall St.
A number of insiders bought Hillstream BioPharma, Inc. (NASDAQ:HILS) stock last year, which is great news for shareholders
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
- GlobeNewswire
Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments
Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint InhibitorsBRIDGEWATER, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced a collaboration with Sapien Biosciences to evaluat
